Spring Hill, TN, United States

Integrity Nutraceuticals

www.integritynutmfg.com/
Spring Hill, TN, United States
SEARCH FILTERS
Time filter
Source Type

Qin B.,U.S. Department of Agriculture | Qin B.,Integrity Nutraceuticals | Anderson R.A.,U.S. Department of Agriculture
British Journal of Nutrition | Year: 2012

Chokeberries are a rich source of anthocyanins, which may contribute to the prevention of obesity and the metabolic syndrome. The aim of the present study was to determine if an extract from chokeberries would reduce weight gain in rats fed a fructose-rich diet (FRD) and to explore the potential mechanisms related to insulin signalling, adipogenesis and inflammatory-related pathways. Wistar rats were fed a FRD for 6 weeks to induce insulin resistance, with or without chokeberry extract (CBE) added to the drinking-water (100 and 200 mg/kg body weight, daily: CBE100 and CBE200). Both doses of CBE consumption lowered epididymal fat, blood glucose, TAG, cholesterol and LDL-cholesterol. CBE consumption also elevated plasma adiponectin levels and inhibited plasma TNF-α and IL6, compared with the control group. There were increases in the mRNA expression for Irs1, Irs2, Pi3k, Glut1, Glut4 and Gys1, and decreases in mRNA levels of Gsk3. The protein and gene expression of adiponectin and Ppar mRNA levels were up-regulated and Fabp4, Fas and Lpl mRNA levels were inhibited. The levels of gene expression of inflammatory cytokines, such as II, I16 and Tnfα were lowered, and protein and gene expression of ZFP36 (zinc finger protein) were enhanced in the epididymal adipose tissue of the rats that consumed the CBE200 extract. In summary, these results suggest that the CBE decreased risk factors related to insulin resistance by modulating multiple pathways associated with insulin signalling, adipogenesis and inflammation. © 2011 The Authors.


Qin B.,U.S. Department of Agriculture | Qin B.,Integrity Nutraceuticals | Polansky M.M.,U.S. Department of Agriculture | Harry D.,U.S. Department of Agriculture | Anderson R.A.,U.S. Department of Agriculture
Molecular Nutrition and Food Research | Year: 2010

Epidemiological studies indicate that the consumption of green tea polyphenols (GTP) may reduce the risk of coronary artery disease. To explore the underlying mechanisms of action at the molecular level, we examined the effects of GTP on the cardiac mRNA and protein levels of genes Accepted: involved in insulin and lipid metabolism and inflammation. In rats fed a high-fructose diet, supplementation with GTP (200mg/kg BW daily dissolved in distilled water) for 6wk, reduced systemic blood glucose, plasma insulin, retinol-binding protein 4, soluble CD36, cholesterol, triglycerides, free fatty acids and LDL-C levels, as well as the pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α) and IL-6. GTP did not affect food intake, bodyweight and heart weight. In the myocardium, GTP also increased the insulin receptor (Ir), insulin receptor substrate 1 and 2 (Irs1 and Irs2), phosphoinositide-3-kinase (Pi3k), v-akt murine thymoma viral oncogene homolog 1 (Akt1), glucose transporter 1 and 4 (Glut1 and Glut4) and glycogen synthase 1 (Gys1) expression but inhibited phosphatase and tensin homolog deleted on chromosome ten (Pten) expression and decreased glycogen synthase kinase 3β (Gsk3β) mRNA expression. The sterol regulatory element-binding protein-1c (Srebp1c) mRNA, microsomal triglyceride transfer protein (Mttp) mRNA and protein, Cd36 mRNA and cluster of differentiation 36 protein levels were decreased and peroxisome proliferator-activated receptor (Ppar)γ mRNA levels were increased. GTP also decreased the inflammatory factors: Tnf, Il1b and Il6 mRNA levels, and enhanced the anti-inflammatory protein, zinc-finger protein, protein and mRNA expression. In summary, consumption of GTP ameliorated the detrimental effects of high-fructose diet on insulin signaling, lipid metabolism and inflammation in the cardiac muscle of rats. © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


A composition containing nelumbo extract reduces and/or eliminates one or more risk factors associated with Metabolic syndrome. The composition also includes optionally one of more components selected from the group consisting of vitamins, cholesterol lowering agents, lipid lowering agents, and glucose lowering agent. Also described is a method of reducing and/or eliminating risk factors associated with Metabolic syndrome in a subject through the administration of the nelumbo extract. The nelumbo extract supplement is administered orally, intravenously, or subcutaneously. In one embodiment, a daily dose of 10-1,000 mg of the extract supplement is administered to the subject for a period of 6 weeks to 6 months.


Patent
Integrity Nutraceuticals | Date: 2013-11-12

Materials derived from Nelumbo are administered orally to humans or animals for the purpose of enhancing creatine transport into skeletal tissue and for purposes of enhancing lean body mass. Enhancing creatine transport through improved insulin signaling is a new method of depositing creatine and enhancing lean body mass. Such administration is also used for enhancing athletic performance and controlling bodyweight and body fat levels. More specifically, such administration is used for the purpose of enhancing creatine transport into excitable tissues such as skeletal muscle. The material is administered as extracts of Nelumbo and administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.


A process for increasing lean body mass in a mammalian subject is provided that includes administering to the subject a purified quantity of maslinic acid, oleanolic acid, or a combination thereof. The administration can be orally and benefits from ingestion of an amino acid source such as dietary protein, oligopeptides, or amino acids. Administration within 2 hours of muscle-degrading exercise or on a daily basis for a period of time increases lean body mass.


A dietary supplement composition comprising aronia extract containing at least 20% anthocyanins by dry weight. The aronia extract is derived from the aronia melanocarpa plant. The aronia extract comprises approximately 10%-30% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is provided in the composition. The dietary supplement composition is administered orally to promote weight loss.


A dietary supplement composition is provided for enhancing the expression of a sirtuin gene or protein. An inventive supplement composition includes at least one cinnamon extract containing at least 0.5% doubly linked Type-A polymers by dry weight. The cinnamon extract is derived from the Cinnamonum aromaticum, Cinnamonum verum or Cinnamonum burmannii plant. In some embodiments, the cinnamon extract is present at approximately 20%-50% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is optionally provided in the composition. The dietary supplement composition is administered orally to promote expression or enhanced expression of a sirtuin gene or protein.


Materials derived from cinnamon can be administered orally to humans or animals for the purpose of controlling blood glucose as well improving glucose tolerance. Controlling glucose metabolism is essential for those with impaired glucose metabolism as is the case for those with Type II diabetes where insulin function is not properly functioning. Such administration can also be used for the purpose of enhancing nutrient transport for purposes of athletic performance and controlling bodyweight and body fat levels. Similarly related, such administration can also be used for the purpose of enhancing creatine transport into excitable tissues such as skeletal muscle. The material can be administered as extracts of cinnamon and can be administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.


A composition containing cinnamon extract reduces and/or eliminates one or more risk factors associated with Syndrome X. The composition also includes optionally one of more components selected from the group consisting of vitamins, cholesterol lowering agents, lipid lowering agents, and glucose lowering agent. Also described is a method of reducing and/or eliminating risk factors associated with Syndrome X in a subject through the administration of the cinnamon extract. The cinnamon extract supplement is administered orally, intravenously, or subcutaneously. In one embodiment, a daily dose of 10-1,000 mg of the cinnamon extract supplement is administered to the subject for a period of 6 weeks to 6 months.

Loading Integrity Nutraceuticals collaborators
Loading Integrity Nutraceuticals collaborators